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Abstract 
 
A recently developed recombinant bovine 
herpesvirus 1 (BHV-1) virus containing the 
envelope protein gp53 of bovine viral diarrhea 
virus (BVDV) type 1, BHV-1 (v1V31), was 
assessed for its ability to protect against BVDV 
in calves.  Four calves were vaccinated 
intranasally with the recombinant BHV-1-BVDV 
vaccine and did not exhibit any clinical signs 
following vaccination.  The vaccine virus was 
recovered from all vaccinated calves on days 8 
through 10 and the replication appeared to be 
restricted to nasal passages.  Twenty-eight days 
after vaccination, the four vaccinated and four 
control calves were challenged with the type 1 
BVDV, strain NY-1.  All calves had slight 
temperature elevations but the clinical signs 
were more severe in the control calves.  The 
platelet counts were significantly depressed in 
the control calves.  Prior to challenge, neither 
group had BVDV serum neutralizing antibody.  
The vaccinated calves developed higher serum 
antibody levels  2 months following challenge, 
indicating a secondary immune response.  
Necropsy was performed six weeks following 
infection.  No latent BHV-1 virus was detected 
from the trigeminal ganglion of any of the 
vaccinated calves. The recombinant BHV-1 
virus vaccine containing a single BVDV protein 
provided partial protection against BVDV 
infection.  
 
Introduction 
 
Bovine viral diarrhea virus (BVDV) and bovine 
herpesvirus 1 (BHV-1) infections are a major 
source of respiratory and reproductive problems 
in cattle (Fields et al., 1996; Ludwig, 1983).  Live 
attenuated BHV-1 vaccine strains are effective 
and have been used safely in cattle for several 
years (Bello et al., 1992).  BVDV vaccines fail to 
control persistent infections, which occur in 
animals that are infected in utero at 40-120 days 
of gestation, and result in lifelong viral shedding.  
Modified-live BVDV vaccines are available, but 
they are not safe to use in pregnant animals.  
Inactivated BVDV vaccines can be used in a 
pregnant animal, but they are inconvenient and 
ineffective at controlling persistent infections 
(Baker, 1995).   
 
BHV-1 is useful as an expression and vaccine 
vector (Bello et al. 1992).  Genes from other 
viruses can be inserted into the BHV-1 
thymidine kinase (TK) gene because the TK 
gene is non-essential for BHV-1 replication in 
cattle and TK-BHV-1 viruses protect pregnant 
cows against abortion (Whetstone et al. 1992).    
This led to the development of the BHV-1-BVDV 
recombinant virus, BHV-1 (v1V31).  The 
glycoprotein 53 (gp53) of BVDV is the major 
target for neutralizing antibody against BVD 
virus.  The gp53 from BVDV was inserted into 
the TK locus of a TK-- BHV-1 genome.  This 
work was done by Dr. L.J. Bello and Dr. W.C. 
Lawrence, University of Pennsylvania (data not 
published).   
 
The use of a BHV-1-BVDV recombinant virus 
vaccine in pregnant cattle to control both BHV-1 
and BVDV abortions and BVDV persistent 
infections of the fetuses is an important and 
promising approach.  This preliminary vaccine 
trial using calves is a model for future trials to 
protect pregnant cows against BHV-1 and BVDV 
infection.  The objective of this study was to 
determine if the BHV-1 recombinant virus 
vaccine was safe and efficacious. 
 
 
Materials and Methods 
 __________________________ 
1 Undergraduate Student 
2 Sr. Microbiologist 
3 Professor 
Viruses and Cells.  The vaccine virus used was 
the recombinant BHV-1 (v1V31) containing gp53 
of the NADL strain of BVDV type 1 was 
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prepared at the University of Pennsylvania in 
Philadelphia, PA.  The cells used for all assays 
were bovine turbinate (Bt) cells. The cells were 
grown in minimum essential media (MEM) 
containing 5% fetal bovine serum (FBS). The 
challenge virus used was type 1 BVDV NY-1 
from the National Veterinary Services 
Laboratory in Ames, IA.  BVDV Singer type 1 
and BVDV A125 type 2 strains were used for the 
BVDV type 1 and type 2 serum neutralization 
assays respectively.  
The vaccinated and control group calves were 
intranasally inoculated with 107.9TCID50/2ml of 
NY-1 BVDV on day 28 of the study.  Nasal 
samples were taken days 28 through 35 to 
monitor for BVDV excretion.  Clinical signs were 
taken every day with the same categories and 
ratings as the pre-challenge period.  Serum 
samples were taken every 7-14 days from 0- 90 
days to monitor for BHV-1 or BVDV 
seroconversion.  Whole blood was taken days 
28 through 38 to count the number of whole 
blood cells and platelets.   
Animals. Eight male, BHV-1 and BVDV 
negative, Holstein calves were used in the 
study.  The calves were four to five months old 
and ranged in weight from 200 to 300 pounds.  
Two groups of calves were used, a vaccinated 
group and a control group, with each group 
consisting of four animals.  The calves were 
initially housed first in an open enclosure with 
calf hutches and later moved to an open-front 
barn in a small pasture enclosure.  The study 
was reviewed and approved by the SDSU 
Institutional Animal Care and Use Committee 
(IACUC). 
 
Virus Isolation and Serology. The nasal samples 
taken after vaccination and challenge were 
collected and virus isolations were performed.  
The secretions were collected by aspiration 
using a vacuum pump. One-half of a milliliter 
(0.5 ml) of nasal secretions were added to 4.5 
ml of MEM containing 1% FBS.  This mixture 
was vortexed, centrifuged and filter sterilized in 
0.45 mm filters.  Duplicates were plated at 1:5 
serial dilutions on Bt cells.  The BHV-1 isolation 
plates after vaccination were read four days 
after inoculation and the cytopathic effect (CPE) 
was recorded.  Seven days after the inoculation, 
the cells on the BVDV isolation plates were fixed 
with 20% acetone, 80% PBS and 0.02% BSA.  
The plates were dried overnight and frozen at -
70°C.  Later a BVDV immunoperoxidase test 
was performed on the cells to detect BVDV in 
the samples (Saliki, 1997).  The viral titers were 
determined using a TCID50 assay (Karber, 
1931). 
 
Vaccination and Challenge Studies.  Calves 
were vaccinated and/or challenged intranasally.  
The calves were secured in a headgate and 
restrained using a rope halter.  A small plastic 
biosafety bag was placed over their muzzles to 
induce hypoxia for 1-2 minutes to increase 
respiration rate and inspiration volume.  The bag 
was removed and the vaccine/challenge was 
administered with a Chromist TLC aerosol unit 
(Gelman Sciences) for one minute to each 
nostril.  The bag was again placed over the 
calves’ muzzles and hypoxia was induced.  The 
halter was removed and the calves were 
released.  
 
Antibody levels for BHV-1 and BVDV were 
determined by a virus neutralization assay using 
two fold dilutions (Manual of Standards for 
Diagnostic Tests and Vaccines, 1992) by the 
Serology Section of the Animal Disease 
Research and Diagnostic Laboratory (ADRDL) 
at SDSU. 
 
The vaccinated calves were intranasally 
inoculated with 107TCID50/2ml of recombinant 
BHV-1-BVDV vaccine on day 0.  Nasal samples 
were taken day 0 to 14 to monitor for 
recombinant BHV-1-BVDV excretion.  Clinical 
signs were taken every day.  The clinical signs 
included respiration, attitude, nasal discharge, 
temperature, and diarrhea.  The clinical signs 
were rated on a 0 to 4 point scale, (i.e. normal 
nasal discharge=0, whereas thick or crusted 
nasal discharge=4).  Serum samples were taken 
every seven days starting at day 0 to monitor for 
seroconversion to recombinant BHV-1-BVDV. 
 
Clinical Pathology.  White blood cell and platelet 
counts were performed by the Clinical Pathology 
section at the ADRDL of SDSU from the whole 
blood on days 27-38 (Days –1 to 10 post 
challenge). 
 
Necropsy.  The calves were all euthanized by 
electrocution at the end of the study on Day 90.  
The tissues harvested were:  tonsil, spleen, 
thymus, testes, Peyer’s patches, trigeminal 
ganglion, and medistineal, mesenteric, 
retropharyngeal, and subiliac lymph nodes.  
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Serology.  The initial development and kinetics 
of BVDV type 1 serum neutralization response 
was similar between the vaccinates and control 
animals with the exception of the BVDV type 1 
titers of the vaccinated group which were higher 
at day 90 (Figure 8).  All of the calves sero-
converted to BVDV type 1 by day 56 of the study 
(28 days post-challenge) (Figure 8). Interestingly 
none of the vaccinated calves seroconverted to 
BHV-1 (data not shown).  The response to 
serotype 2 was low indicating low cross 
reactivity between BVDV type 1 NY-1 strain and 
BVDV type 2 A125 (Figure 8).  The values for 
Calf #4 were excluded from the data because of 
a high outlying BVDV type 2 titer on a single 
day. 
Paired tissue samples were taken, one set was 
fresh and one set was preserved in formalin.  
The fresh tissues were frozen in  -80°C.  Virus 
isolations were performed on these samples. 
 
Statistical Analysis.  The results were analyzed 
using a student's T-test for statistical 
significance. 
 
Results 
 
Growth of Recombinant Virus and Clinical Signs 
following Vaccination.  BHV-1 was recovered 
from all animals from days 3-10 days post-
vaccination (Figure 1).  The most consistent 
days were days 8-10. Titers of the recombinant 
recovered from the nasal secretions were as 
high as 106 TCID50/ml. 
 
Discussion 
  
This study established that a recombinant BHV-
1-BVDV was safe to use in calves.  The calves 
showed minimal reactions to the vaccine as 
measured by body temperatures and clinical 
scores.  These minimal symptoms coincided 
with the detection of the recombinant BHV-1-
BVDV shedding in the nasal secretions of the 
vaccinated calves (Figure 1).  This indicated that 
local replication occurred.  Interestingly, no 
apparent systemic replication occurred as no 
latency could be detected in the trigeminal 
ganglia during the necropsy.   
The post-vaccination temperatures were normal 
(Figure 2) and clinical scores for post-
vaccination were negligible (Figure 3) with a 
very slight increase seen from days 5-8.   
 
Clinical Signs and Virus Isolation Following 
Challenge.  BVDV was not detected from any 
nasal samples after challenge (data not shown). 
No latent BHV-1 was detected from the 
trigeminal ganglion of any of the vaccinated 
calves (data not shown) 
 
 The post-challenge temperatures of the 
vaccinated and control calf groups were similar 
(Figure 4).  The post-challenge clinical scores 
showed an increase in signs during day 5 to 6 
and day 8 to 9 with the control group scores 
always higher (Figure 5).  However none of the 
differences were significant. 
After challenge, the vaccinated animals 
exhibited less clinical disease than the controls 
although none of the differences were significant 
(p>0.10). The clinical pathology results indicated 
a significant increase in white blood cells in the 
control animals on day 35 while there was no 
effect on the vaccinated animals.  Transient 
leukopenia normally associated with BVDV 
infection did not occur in this study.  There was 
a significant thrombocytopenia present in the 
control animals on days 34, 36 and 37. 
 
Clinical Pathology.  The white blood cell (WBC) 
count of both the vaccinated and control calf 
group declined on days 1-2 post challenge 
(Days 29 and 30) (Figure 6). The vaccinated 
calves remained slightly lower than normal on 
days 4-6 post challenge and returned to normal 
on day 7.  The control calves WBC count was 
returned to normal on day 5 post-challenge and 
increased significantly on day 7 (p <0.10) 
(Figure 6).  The platelet count of the vaccinated 
calf group remained normal after challenge, 
while the control calf group’s count was 
depressed significantly on days 34 (p<0.1), 36 
(p<0.001) and 37 (p<0.05) (Figure 7). 
 
Serum neutralizations indicated the 
development of neutralizing antibody titers to 
BVDV type 1, but not to the BVDV type 2 (Figure 
8).  This shows the specificity of type 1 gp53 for 
type 1 and not for BVDV type 2.  After the 
challenge there was an increase in the 
vaccinated BVDV type 1 titer at 90 days post 
vaccination compared to the control BVDV type 
1 titers.  This represents a secondary immune 
response in the vaccinated animals, showing the 
vaccine had induced memory cell development 
to BVDV. 
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In conclusion, this small pilot study suggests a 
role for a recombinant BVDV-BHV-1 vaccine in 
the control of respiratory and reproductive 
disease caused by these two viruses.  Calves 
vaccinated with recombinant BHV-1-BVDV virus 
vaccine showed no adverse reactions to the 
vaccine and the vaccine replicated locally in the 
respiratory tract.  There were differences in the 
post-challenge clinical scores and type 1 BVDV 
serum neutralization titers and significant 
differences in the WBC and platelet counts 
between the vaccinated and control calves.  The 
recombinant BHV-1-BVDV vaccine provided 
partial protection against a BVDV challenge.  
This study suggests a trial with pregnant cows 
would provide significant information towards 
creating a successful vaccine to control both 
BHV-1 and BVDV abortions and BVDV 
persistent infections of the fetus. 
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Fig.1 Recombinant BHV-1 shedding in nasal secretions after intra-nasal 
inoculation.
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Fig. 2 Post-vaccination average calf rectal-temperature values.
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Fig. 3  Average post-vaccination calf clinical scores.
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Fig. 4 Body Temperatures following BVDV Challenge
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Fig. 5 Clinical Scores following BVDV Infection
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Fig. 6 White Blood Cell Counts following BVDV Infection
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Fig.8: Singer "BVDV-1" and A125 "BVDV-2" average neutralizing antibody titers in 
sera of vaccinated and control calves.
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